SRRK - スカラ―・ロック・ホ―ルディング (Scholar Rock Holding Corporation)

SRRKのニュース

   Scholar Rock climbs on Phase 2 data for spinal muscular atrophy therapy  2021/06/11 17:19:02 Seeking Alpha
   Scholar Rock to Present Apitegromab Clinical Data from the TOPAZ Phase 2 Trial in Patients with Type 2 and 3 Spinal Muscular Atrophy at the 2021 Virtual SMA Research & Clinical Care Meeting  2021/06/07 00:00:00 BioSpace
Scholar Rock (NASDAQ: SRRK), a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, today announced an oral presentation of apitegromab TOPAZ Phase 2 clinical trial results at the 2021 Virtual SMA Research and Clinical Care Meeting, being held in conjunction with Cure SMAs Annual SMA Conference June 7-11, 2021.
   Scholar Rock to Present at Upcoming Healthcare Conferences in June  2021/05/27 00:00:00 BioSpace
Scholar Rock (NASDAQ: SRRK), a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, today announced that management will participate in the following upcoming investor conferences: Jefferies Virtual Healthcare Conference on Wednesday, June 2 nd , 2021 at 11:00 a.m. ET.
   Scholar Rock''s apitegromab gets Fast Track designation; shares up 9% after-hours  2021/05/24 20:22:26 Seeking Alpha
   Scholar Rock Receives Fast Track Designation from the U.S. FDA for Apitegromab for the Treatment of Patients with Spinal Muscular Atrophy  2021/05/24 00:00:00 BioSpace
Scholar Rock (NASDAQ: SRRK), a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for apitegromab
   Scholar Rock Announces Senior Management Promotions  2021/02/04 21:30:00 Business Wire
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, today announced that its Board of Directors has approved several promotions within the senior management team, including Gregory Carven, Ph.D. to Chief Scientific Officer, Junlin Ho, J.D. to General Counsel and Corporate Secretary, and George Nomikos, M.D., Ph.D. to Senior Vice President,
   Scholar Rock Presents Preclinical Data for SRK-181 at the TGFβ for Immuno-Oncology Drug Development Summit  2021/01/27 13:00:00 Business Wire
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, today announced a presentation at the 2021 TGFβ for Immuno-Oncology Drug Development Summit. “Inhibition of TGFβ1 Activation with SRK-181 Overcomes Primary Resistance to Checkpoint Inhibition Therapy” will be presented on January 28th, 2021 at 12:30 PM EST. The presentation will provide an
   Scholar Rock Provides Corporate Update and Highlights Priorities for 2021  2021/01/11 12:30:00 Business Wire
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, today provided a corporate update and highlighted priorities for 2021. “2020 was a transformative year for Scholar Rock with significant progress made both clinically and operationally with positive interim data from the TOPAZ trial providing initial proof-of-concept of apitegromab’s poten
   Scholar Rock to Present at the 39th Annual J.P. Morgan Healthcare Conference  2021/01/04 21:01:00 Business Wire
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, today announced that management will present at the 39th Annual J.P. Morgan Healthcare Conference on Monday, January 11, 2021 at 5:20 p.m. ET. A live webcast of the presentation may be accessed by visiting the Investors & Media section of the Scholar Rock website at http://investors.sc
   Scholar Rock Reports Third Quarter 2020 Financial Results and Highlights Business Progress  2020/11/09 13:00:00 Business Wire
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, today reported financial results for the third quarter ended September 30, 2020 and highlighted recent progress and upcoming milestones for its pipeline programs. “We achieved a significant milestone with the TOPAZ interim analysis proof-of-concept results. The data support apitegromab’s p
   Scholar Rock Announces Senior Management Promotions  2021/02/04 21:30:00 Business Wire
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, today announced that its Board of Directors has approved several promotions within the senior management team, including Gregory Carven, Ph.D. to Chief Scientific Officer, Junlin Ho, J.D. to General Counsel and Corporate Secretary, and George Nomikos, M.D., Ph.D. to Senior Vice President,
   Scholar Rock Presents Preclinical Data for SRK-181 at the TGFβ for Immuno-Oncology Drug Development Summit  2021/01/27 13:00:00 Business Wire
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, today announced a presentation at the 2021 TGFβ for Immuno-Oncology Drug Development Summit. “Inhibition of TGFβ1 Activation with SRK-181 Overcomes Primary Resistance to Checkpoint Inhibition Therapy” will be presented on January 28th, 2021 at 12:30 PM EST. The presentation will provide an
   Scholar Rock Provides Corporate Update and Highlights Priorities for 2021  2021/01/11 12:30:00 Business Wire
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, today provided a corporate update and highlighted priorities for 2021. “2020 was a transformative year for Scholar Rock with significant progress made both clinically and operationally with positive interim data from the TOPAZ trial providing initial proof-of-concept of apitegromab’s poten
   Scholar Rock to Present at the 39th Annual J.P. Morgan Healthcare Conference  2021/01/04 21:01:00 Business Wire
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, today announced that management will present at the 39th Annual J.P. Morgan Healthcare Conference on Monday, January 11, 2021 at 5:20 p.m. ET. A live webcast of the presentation may be accessed by visiting the Investors & Media section of the Scholar Rock website at http://investors.sc
   Scholar Rock Reports Third Quarter 2020 Financial Results and Highlights Business Progress  2020/11/09 13:00:00 Business Wire
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, today reported financial results for the third quarter ended September 30, 2020 and highlighted recent progress and upcoming milestones for its pipeline programs. “We achieved a significant milestone with the TOPAZ interim analysis proof-of-concept results. The data support apitegromab’s p

calendar